Novartis AG and AstraZeneca Plc could both take heart this week from results of separate drug trials that analysts expect to boost the clinical case for their products. Data on Novartis’s Diovan blood pressure drug as a post-heart attack treatment will be presented at the American Heart Association meeting in Orlando at 9 a.m. EST on Monday, with news on AstraZeneca’s experimental anti-coagulant Exanta due a day later.
